Top Markets
Coin of the day
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Rank in Stocks #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Share Price
$0.05207079
Last synced: 2023-11-15
Market Cap
$3.38M
Change (1 day)
0.13%
Change (1 year)
0.00%
Country
AU
Trade Kazia Therapeutics Limited (KZA)

Category

P/B ratio for Kazia Therapeutics Limited (KZA)
P/B ratio as of 2026 TTM: 0
According to Kazia Therapeutics Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Kazia Therapeutics Limited from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE